Elanco, the animal health division of Eli Lilly, reported an agreement to acquire Lohmann SE (Lohmann Animal Health), a privately-held company headquartered in Cuxhaven, Germany. Lohmann Animal Health is a leader in the supply of poultry vaccines and also markets a range of feed additives. The acquisition will establish Elanco as a poultry provider, solidify Elanco's vaccine presence, broaden Elanco's product offerings, and expand Elanco's vaccine manufacturing capabilities, the company says.
Under the terms of the agreement, Lilly will acquire all assets of Lohmann SE and its subsidiary, Lohmann Animal Health. These assets include a range of vaccines and feed additives, commercial capabilities, and manufacturing sites in Cuxhaven, Germany and Winslow, Maine. No other terms of the transaction were disclosed.
The transaction is expected to close in the second quarter of 2014, contingent upon clearance from regulatory authorities and other customary closing conditions.